379-P: Population Response to Home Use of Mini-dose Glucagon as a Treatment for Hypoglycemia following Repeated, Prolonged Fasts in Type 1 Diabetes during Ramadan

Objective: The extent of public interest of home use of mini-dose glucagon (MDG) as a new approach for managing hypoglycemia during Ramadan prolonged fasts prompted the authors to make available, on a on social media, general information about study protocol, both for people with diabetes and healthcare professionals. Shortly thereafter, individuals began to feed back their personal experiences. We have collated this information using a structured online survey outside a research setting Methods: Emails, private messages in X (twitter) and WhatsApp communications between May 2021 and April 2023 were evaluated (n = 136). An online survey was sent to collect the feedback of using MDG Results: After using MDG, 123 (91%) of participants reported they were able to complete their fasts and 110 (80%) of participants they report will prefer to use MDG in the future to correct fasting induced hypoglycemia. Furthermore, participants showed significant change in their habits with more than half stop raise their blood sugar above the target at Sahour time and more than half start to correct the previous ignored hypoglycemia even if it was occurred within an hour of Iftar time Conclusions: These data demonstrate that MDG administration is an effective as home treatment for fasting-induced hypoglycemia and encourage the change of unhealthy habits to avoid breaking the fast